Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha/beta T-cell and CD19 B-cell depleted allogeneic stem cell transplantation followed by innate donor lymphocyte infusion in high-risk or relapsed acute leukemia/MDS
NL-OMON35919Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Aug 2011
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic hematopoietic stem cells, innate donor lymphocyte infusion and ciclosporin in Acute Leukaemia and myelodysplastic syndrome (MDS), sponsored by University Medical Center Utrecht. Primary endpoints: Feasibility, Graft-versus-host disease incidence and 1 more. Started Aug 2011; status: active, not recruiting.
02
Drugs
allogeneic hematopoietic stem cellsinnate donor lymphocyte infusionciclosporin
03
Conditions
Acute Leukaemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON35919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35919.